SQZB

0.02400.00%
AW

Amy W. Schulman

Independent Chair of the Board

Ms. Amy W. Schulman, J.D., serves as Managing Partner of Polaris Growth Management, L.L.C., which she joined in 2014. She also serves as Managing Partner of LS Polaris Innovation Fund Management, L.L.C. and as a managing partner at Polaris Partners. In 2017, she co-founded the Polaris Innovation Fund, which she continues to manage. She serves as Independent Chair of the Board of Alnylam Pharmaceuticals, Inc. since January 2023. She serves as Independent Director of Elevance Health, Inc. She serves as Director of SQZ Biotechnologies Company since October 2022. She serves as Chief Executive Officer of Olivo Laboratories, LLC. She serves as Member of Board of Directors of TriGemX Bio, Inc. She serves as Director of Tessa Therapeutics Pte Ltd. since March 2022 and as Director of Tessa Therapeutics Inc. since January 2023. She serves as Director of Blue Buffalo Company, Ltd. since November 10, 2014. She serves as Director of Engine Biosciences Pte. Ltd. since May 26, 2021. She serves as Director of QurAlis Corporation. She serves as Director of Thirty Madison, Inc. since August 14, 2020. She serves as Chair of the Board of ByHeart, Inc. She serves as Director of Amagma, Inc. She serves as Director of Vico Therapeutics B.V. since July 29, 2020. She serves as Independent Director of Hudson Executive Investment Corp. II since January 25, 2021. She serves as Director of Noetik Inc. since August 2024. She serves as Independent Director of ClavystBio Pte Ltd. She serves as Chair of Board of Directors of Larkspur Biosciences Inc. She serves as Director of Sequelae, Inc. She serves as Director of Delphia Therapeutics, Inc. She serves as a Senior Lecturer at Harvard Business School’s Faculty, which she joined in July 2014. She also serves on the Boards of Action Against Hunger, Mount Sinai Hospital, the California Institute of Technology, Singapore’s Human Health and Potential International Advisory Council, and Singapore’s Research, Innovation and Enterprise Council. Ms. Schulman served as Independent Director of Fractyl Health, Inc. from September 2018 to September 2025. At SQZ Biotechnologies Company, she also served as Chairwoman from 2020 to October 2022 and as Executive Chairwoman until 2020. At Alnylam Pharmaceuticals, Inc., she also served as Lead Independent Director from August 2021 to January 2023 and as Independent Director from July 2014 to August 2021. She served as Independent Director of Cyclerion Therapeutics, Inc. from April 1, 2019 to December 16, 2020. She is Co-Founder of Lyndra Therapeutics, Inc. and also served as Executive Chair of the Board from 2019 and as Chief Executive Officer, President, Treasurer & Director until 2019. She served as Director of Ironwood Pharmaceuticals, Inc. from January 1, 2017 to April 1, 2019. She served as Director of Blue Buffalo Pet Products, Inc. from 2014 to April 24, 2018. She served as Director of DNIB Unwind, Inc. from September 2014 to June 17, 2016. She served as Lead Independent Director of Arsanis, Inc. from February 2015. She served as Executive Vice President, General Counsel and Business Unit Lead of Consumer Healthcare at Pfizer Inc., where she was employed from June 2008 to December 2013. At Pfizer, she also served as president of both Pfizer Nutrition and Pfizer Consumer Healthcare. She served as Director of Zoetis Inc. from July 2012 to June 2013. Her prior experience includes serving as Director of Volastra Therapeutics, Inc. from April 6, 2021, Independent Director of Hudson Executive Investment Corp. from June 8, 2020, Director of Cardurion Pharmaceuticals, Inc. from November 2019, Non-Employee Director of X4 Pharmaceuticals, Inc., Chief Executive Officer of Eagle Biologics, Inc., Director of Suono Bio, Inc., Director of Glympse Bio, Inc. and Trustee of Brooklyn Academy Of Music Inc. She practiced law as a partner at DLA Piper and began her career in litigation with Cleary Gottlieb Steen & Hamilton in 1991. Ms. Schulman focuses on investing in healthcare companies, early stage biotech start-ups and start-ups. She has received numerous recognitions, including being named to Forbes’ 50 Over 50 list in 2025, Fortune Magazine’s 50 Most Powerful Women in Business, the Margaret Brent Women Lawyers of Achievement Award, Scientific American’s Worldview 100 List and Fierce Biotech’s Top 15 Women in Biotech. She is a Phi Beta Kappa graduate of Wesleyan University, where she received a B.A. in Philosophy & English in 1982 and Yale Law School, where she received a J.D. in 1989.

Positions